Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.51 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29731764 | 1.00 | BTK (0.51) | BTKCDK4CCNA2CCND1CCNE1 | |
| SCHEMBL29741805 | 1.00 | BTK (0.51) | BTKCDK4CCNA2CCND1CCNE1 | |
| SCHEMBL14916485 | 1.00 | BTK (0.51) | BTKCDK4CCNA2CCND1CCNE1 | |
| SCHEMBL29741961 | 1.00 | BTK (0.51) | BTKCDK4CCNA2CCND1CCNE1 | |
| SCHEMBL14915756 | 1.00 | BTK (0.51) | BTKCDK4CCNA2CCND1CCNE1 | |
| Hydrochloric Acid SCHEMBL30448465 | 0.99 | BTK (0.51) | BTKCDK4CCNA2CCND1CCNE1 | |
| SCHEMBL29731766 | 0.94 | BTK (0.46) | BTKCDK4CCNA2CCND1CCNE1 | |
| SCHEMBL14916289 | 0.88 | BTK (0.43) | BTKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL14916288 | 0.88 | BTK (0.43) | BTKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL29742041 | 0.88 | BTK (0.43) | BTKCDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058457-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-RE48239-E1 | Heteroaryl pyridone and aza-pyridone compounds | GENETECH, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| CN-107011348-B | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of BTK activity | 霍夫曼-拉罗奇有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3521288-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2019-08-07 | — | — | EP | disclosed |
| US-8729072-B2 | Alkylated piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2013067264-A1 | 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067274-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067277-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | BTK, LCK, SYK | BTK 1/4885CDK4 644/4885CCNA2 1215/4885 |
| US-20240058457-A1 | BTK DEGRADER | BTK, LYN, SYK | BTK 1/4885CDK4 426/4885CCNA2 1050/4885 |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | BTK 1/4885CDK4 747/4885CCNA2 1579/4885 |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885CDK4 170/4885CCNA2 1449/4885 |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | BTK, LCK, SYK | BTK 1/4885CDK4 618/4885CCNA2 1776/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885CDK4 170/4885CCNA2 1449/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | BTK 1/4885CDK4 170/4885CCNA2 905/4885 |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885CDK4 170/4885CCNA2 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.